Interstitial pneumonitis induced by pegylated liposomal doxorubicin in a patient with recurrent ovarian cancer

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 1255-1257

  Inaba, Kanako ^a   Arimoto, Takahide ^a   Hoya, Mari ^a   Kawana, Kei ^a   Nakagawa, Shunsuke ^a   Kozuma, Shiro ^a   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Drug induced; Interstitial pneumonitis; Japanese; Ovarian cancer; Pegylated liposomal doxorubicin

Indexed keywords

ASCORBIC ACID; AZITHROMYCIN; BROTIZOLAM; C REACTIVE PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CEFEPIME; DOXORUBICIN; IRINOTECAN; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; PACLITAXEL; PYRIDOXAL 5 PHOSPHATE; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADULT; ARTERIAL GAS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FEVER; HUMAN; HYPOXIA; INTERSTITIAL PNEUMONIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LUNG FUNCTION TEST; LUNG INFILTRATE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVARY CARCINOMA; OXYGEN SATURATION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE OXIMETRY; RECURRENT CANCER; STEROID THERAPY; THORAX RADIOGRAPHY; TREATMENT WITHDRAWAL; CANCER STAGING; CHEMICALLY INDUCED DISORDER; CYSTADENOCARCINOMA; INTERSTITIAL LUNG DISEASE; MIDDLE AGED; OVARY TUMOR; TUMOR RECURRENCE;

CYSTADENOCARCINOMA, SEROUS; DOXORUBICIN; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84866279026     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-9893-0     Document Type: Article

References (10)

1. Gordon AN, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-22.
2. Gordon AN, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95: 1-8.
3. Ferrandina G, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26:890-6.
4. Uziely B, et al. Liposomal doxorubicin: antitumor activity and unique toxicity during two complementary phase I studies. J Clin Oncol. 1995;13:1777-85.
5. Thigpen JT, et al. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 2005;96:10-8.
6. Huober J, Schoch O, Templeton A, Christian S, Thurlimann B. Interstitial pneumonitis after treatment with bevacizumab and pegylated liposomal doxorubicin in a patient with metastatic breast cancer. Chemotherapy. 2010;56:69-70.
7. Kim KM, et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J. 2008;49(1):155-8.
8. Satoh H, Kurishima K, Ishikawa H, Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med. 2006;260:429-34.
9. Cohen MH, Williams GA, Sridhara R, Chan G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8(4):303-6.
10. Takeishi M, et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005;32(6):1160-3.